Lamivudine bound in HBV polymerase

Evivar Medical is a joint venture company established in February 2006 to provide accurate and timely therapy management for Hepatitis B patients through its SeqHepB programme - a web-based decision support tool to assist physicians to optimise and individualise the treatment schedule of patients with chronic hepatitis B.

The SeqHepB system can be used to identify HBV mutations present in the patient and to determine resistance levels to the various available medications. SeqHepB is a unique viral genomics sequence analysis program that is linked to a HBV genomic database.

Evivar provides a secure, on-line decision support tool for those treating patients with HBV. Evivar enables physicians to individualise the treatment of patients with chronic HBV, selecting the right drug, at the right time in response to the mutations diagnosed.

Hepatitis B ('HBV') is one of the top 10 causes of mortality globally. There are 360 million individuals worldwide suffering chronic HBV, with a further estimated 7 million people becoming chronically infected each year.

Like many infectious diseases, HBV mutates in response to drug treatments. The emergence of these mutants, without the appropriate therapy management, leads to treatment failure resulting in progression of liver disease, a rapidly diminishing quality of life and ultimately, in many cases, mortality.